---
title: "Key facts: NASDAQ:GPCR Aleniglipron 16.2% Loss; CEO: Safety, Lower Costs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299727604.md"
description: "Structure Therapeutics (GPCR) reported Phase 2 extension: oral GLP‑1 Aleniglipron showed up to 16.2% mean weight loss at 72 weeks, no plateau, low discontinuations after lower starting dose. StocktwitsStructure Therapeutics (GPCR) CEO Ray Stevens said GPCR’s aleniglipron shows strong efficacy, no drug-related liver injury, and lower manufacturing costs versus Novo Nordisk and Lilly. StocktwitsDisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources."
datetime: "2026-09-22T07:15:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299727604.md)
  - [en](https://longbridge.com/en/news/299727604.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299727604.md)
generator: "portal-rs"
---

# Key facts: NASDAQ:GPCR Aleniglipron 16.2% Loss; CEO: Safety, Lower Costs

-   Structure Therapeutics (GPCR) reported Phase 2 extension: oral GLP‑1 Aleniglipron showed up to 16.2% mean weight loss at 72 weeks, no plateau, low discontinuations after lower starting dose. Stocktwits
-   Structure Therapeutics (GPCR) CEO Ray Stevens said GPCR’s aleniglipron shows strong efficacy, no drug-related liver injury, and lower manufacturing costs versus Novo Nordisk and Lilly. Stocktwits

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

### Related Stocks

- [GPCR.US](https://longbridge.com/en/quote/GPCR.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovy® Pill](https://longbridge.com/en/news/300550399.md)
- [Novo Nordisk strikes second licensing deal since frosty capital-markets day](https://longbridge.com/en/news/300413751.md)
- [Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data](https://longbridge.com/en/news/300461344.md)
- [Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis](https://longbridge.com/en/news/300421791.md)
- [Daiwa: HENGRUI PHARMA  Reaches Licensing Agreement With Novo Nordisk for HRS-1596; Total Deal Value and Upfront Payment Attractive](https://longbridge.com/en/news/300534201.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**